Associated Genetic Biomarkers
Forkhead box O1 (FOXO1) is a gene that encodes a transcription factor protein that functions in insulin signaling and the regulation of metabolic homeostasis in the presence of oxidative stress. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift deletions, and in-frame deletions are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.
FOXO1 is altered in 1.16% of all cancers with colon adenocarcinoma, breast invasive ductal carcinoma, lung adenocarcinoma, follicular lymphoma, and prostate adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in FOXO1 are FOXO1 Mutation (0.85%), FOXO1 Loss (0.30%), FOXO1 Amplification (0.17%), FOXO1-FGFR1 Fusion (0.29%), and FOXO1 Fusion (0.11%) .
FOXO1 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain FOXO1 status as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).
Trials with FOXO1 status in the inclusion eligibility criteria most commonly target soft tissue sarcoma .
The most frequent alterations to serve as inclusion eligibility criteria are FOXO1 Fusion and PAX3-FOXO1 Fusion .
Kb-0742 is the most frequent therapy in trials with FOXO1 as an inclusion criteria .
Significance of FOXO1 in Diseases
Non-Hodgkin Lymphoma +
Soft Tissue Sarcoma +
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.